Visionary leadership
A nimble, visionary company requires exceptional leadership. Kalypsys is lead by an experienced team of executives that are dedicated to providing the next generation of medicines in a collaborative culture that promotes innovation, employee excellence, and professional development. Get to know the remarkable team leading Kalypsys into the future.
Simon Allen (Chief Executive Officer)
Simon Allen is the Chief Executive Officer of Kalypsys. Mr. Allen has 17 years experience in the areas of scientific research, product development, capital markets, and business development. Last serving as the Chief Business Officer of Kalypsys, Mr. Allen has held increasing levels of responsibility at companies such as CovX, Nuvelo, SkyePharma and Gilead. He graduated from the University of Sydney with a B.S. in Biochemistry and Genetics and earned his M.B.A. from the Australian Graduate School of Management. Back to Top
Neil Reisman (Chief Operating Officer)
Neil Reisman is Chief Operating Officer of Kalypsys. Mr. Reisman has over 22 years of business and legal experience. Prior to joining Kalypsys, Mr. Reisman worked in various capacities at various large and small companies including CovX, Amoco, Borg-Warner Security, Comdisco and Arthur Andersen. Mr. Reisman received his J.D. from the University of Pennsylvania and his B.S. in Accounting from the University of Illinois. He is also a Certified Public Accountant. Back to Top
Stewart Noble, Ph.D. (Sr. VP Drug Discovery)
Stewart Noble is Sr. Vice President and Head of Research. Dr. Noble came to Kalypsys from Pharmacia where he served as Senior Director of Chemistry with responsibility for programs targeting arthritis, inflammation, pain and ophthalmology. Prior to joining Pharmacia, Dr. Noble’s industry experience included senior positions at G.D. Searle, Synaptic Pharmaceutical Corporation and Glaxo, Inc. He has 25 years experience in small molecule drug discovery and has contributed to the discovery and development of seventeen product candidates, including the HIV/HBV drug Epivir®. He is author or coauthor of more than 80 peer reviewed scientific papers, patents and pending applications. Dr. Noble is a member of the Board of Directors of Micell Technologies, Inc. Back to Top